Cadila gets USFDA nod for Desmopressin Nasal Spray Solution USP
The shares of Cadila Healthacre
surged by over 3% after the company announced that it has received the
final approval from the USFDA to market Desmopressin Nasal Spray
Solution USP, 10 mcg/0.1 mL per spray, 5mL bottle.
It will manufacture at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria and polydipsia following head trauma or surgery in the pituitary region and nocturia.
The stock was trading up by 3.36% at Rs 490 per share on BSE at 1343 hours. The stock has touched its intraday high and low at Rs 491.65 and Rs 471.60 per share respectively.
The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY04.
It will manufacture at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria and polydipsia following head trauma or surgery in the pituitary region and nocturia.
The stock was trading up by 3.36% at Rs 490 per share on BSE at 1343 hours. The stock has touched its intraday high and low at Rs 491.65 and Rs 471.60 per share respectively.
The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY04.
Comments
Post a Comment